CAS 99873-43-5
:Droxinostat
Description:
Droxinostat is a chemical compound classified as a histone deacetylase (HDAC) inhibitor, which plays a significant role in the regulation of gene expression. It is primarily investigated for its potential therapeutic applications in cancer treatment and other diseases characterized by abnormal cell growth. The compound exhibits a unique mechanism of action by altering the acetylation status of histones, leading to changes in chromatin structure and gene transcription. Droxinostat is known for its ability to induce cell cycle arrest and apoptosis in cancer cells, making it a subject of interest in oncology research. Additionally, it may have implications in the treatment of neurodegenerative disorders due to its effects on neuronal survival and function. The substance is typically administered in a controlled setting, and its pharmacokinetics, safety profile, and efficacy are subjects of ongoing clinical studies. As with many HDAC inhibitors, potential side effects may include gastrointestinal disturbances and hematological changes, necessitating careful monitoring during treatment.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
Droxinostat
CAS:Droxinostat (NS 41080) is a selective inhibitor of HDAC, mostly for HDACs 6 and 8 with IC50 of 2.47 μM and 1.46 μM, greater than 8-fold selective against HDAC3Formula:C11H14ClNO3Purity:99.83%Color and Shape:White SolidMolecular weight:243.69
